Sign in

MLSS on NYSE

MILESTONE SCIENTIFIC INC.

MILESTONE SCIENTIFIC INC. is an American orthopedic company that raised $2.1 million in 2026 (SEC Form D).1 It is headquartered in Livingston, New Jersey.1 Its shares trade on NYSE under the symbol MLSS.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with LogicMark, Inc., Jin Medical International Ltd. or ENvue Medical, Inc., or pick any stock.

  • TickerMLSS on NYSE1
  • IndustryOrthopedic, Prosthetic & Surgical Appliances & Supplies1
  • HeadquartersLivingston, New Jersey1
  • Incorporated inDE2
  • Business address220 South Orange Avenue, Livingston, Nj 070392
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

DPS Dynamic Pressure Sensing® technology, Safety Wand®, STA Single Tooth Anesthesia System®, and The Wand®.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

71.4%Gross margin5
-63.5%Operating margin5
-63.8%Net margin5
4.0%Revenue growth, 20255
-203.4%Return on equity5
-$2.9MFree cash flow5

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Business segments

Dental brought in 49% of the revenue MILESTONE SCIENTIFIC INC. broke down this way in fiscal 2025.

  1. Dental$8.8M549%up 3% from 2024
  2. Dental$8.8M549%up 3% from 2024
  3. Medical$183.2K51%up 75% from 2024
  4. Medical$183.2K51%up 75% from 2024
Business segments by year
Business segments20242025
Dental$8.5M$8.8M
Dental$8.5M$8.8M
Medical$104.6K$183.2K
Medical$104.6K$183.2K

Regions

United States brought in 55% of the revenue MILESTONE SCIENTIFIC INC. broke down this way in fiscal 2025.

  1. United States$5.0M555%down 5% from 2024
  2. Rest of World$3.7M541%up 9% from 2024
  3. [Canada]$310.0K53%
Regions by year
Regions20242025
United States$5.3M$5.0M
Rest of World$3.4M$3.7M
[Canada]$310.0K

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Cost of revenue18¢$2.6M
  • Research and development3¢$449.5K
  • Selling, general and admin79¢$11.6M

Out of $9.0M in revenue.5 The company lost money this year.

Financial statements

Revenue6789105$9.0M in 2025+7% since 2019
0$5.0M$10.0M$15.0M2019: $8.4M$8.4M20192020: $5.4M$5.4M2020−35%2021: $10.3M$10.3M2021+90%2022: $8.8M$8.8M2022−15%2023: $9.8M$9.8M2023+12%2024: $8.6M$8.6M2024−12%2025: $9.0M$9.0M2025+4%
Gross profit6789105$6.4M in 2025+12% since 2019
0$2.0M$4.0M$6.0M$8.0M2019: $5.7M$5.7M20192020: $3.6M$3.6M2020−37%2021: $6.3M$6.3M2021+74%2022: $4.9M$4.9M2022−22%2023: $6.8M$6.8M2023+39%2024: $6.4M$6.4M2024−5%2025: $6.4M$6.4M2025−0%
Operating income6789105-$5.7M in 2025+42% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$4.0M-$4.0M20192020: -$7.5M-$7.5M2020+86%2021: -$7.4M-$7.4M2021−1%2022: -$8.8M-$8.8M2022+20%2023: -$7.1M-$7.1M2023−19%2024: -$6.8M-$6.8M2024−5%2025: -$5.7M-$5.7M2025−16%
Net income6789105-$5.7M in 2025−24% since 2019
-$10.0M-$7.5M-$5.0M-$2.5M02019: -$7.5M-$7.5M20192020: -$7.3M-$7.3M2020−2%2021: -$6.8M-$6.8M2021−7%2022: -$8.7M-$8.7M2022+28%2023: -$6.9M-$6.9M2023−20%2024: -$4.7M-$4.7M2024−32%2025: -$5.7M-$5.7M2025+21%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Product sales, net$9.0M$8.6M
Cost of products sold$2.6M$2.2M
Gross profit$6.4M$6.4M
Selling, general and administrative expenses$11.6M$12.3M
Research and development expenses$449.5K$858.8K
Depreciation and amortization expense$78.2K$37.4K
Total operating expenses$12.1M$13.2M
Loss from operations-$5.7M-$6.8M
Interest (expense) income, net-$25.6K$60.3K
Gain on sale of net operating losses$2.0M
Loss before provision for income taxes-$5.7M-$4.7M
Net loss-$5.7M-$4.7M
Net loss per share applicable to common stockholders - basic-$0.07-$0.06
Net loss per share applicable to common stockholders - diluted-$0.07-$0.06
Weighted average shares outstanding and to be issued - basic82.1M shares79.8M shares
Weighted average shares outstanding and to be issued - diluted82.1M shares79.8M shares

Compare MILESTONE SCIENTIFIC INC. with another company

Corporate structure

MILESTONE SCIENTIFIC INC. sits at the top of its group. 3 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MILESTONE SCIENTIFIC INC.

  • S.r.l. Bp4 Filed SCHEDULE 13D/A on MILESTONE SCIENTIFIC INC., latest Feb 7, 2025
  • MILESTONE SCIENTIFIC INC. Livingston, New Jersey
    • Milestone Innovations Inc. Subsidiary · Delaware, United States
    • Wand Dental , Inc. Subsidiary · Delaware, United States

Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MILESTONE SCIENTIFIC INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$19.2K5 Dec 31, 2025$12.9K5 Dec 31, 2024+48.5%
Finance-lease assets$55.8K5 Dec 31, 2025$67.2K5 Dec 31, 2024−16.9%
Operating-lease assets (leased space)$150.4K5 Dec 31, 2025$257.8K5 Dec 31, 2024−41.7%

Real estate and locations

ItemLatestA year beforeChange
Countries it operates in4110 Dec 31, 2024609 Dec 31, 2023−31.7%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.1M5 Dec 31, 2025$3.3M5 Dec 31, 2024−65.8%
Marketable securities, current$010 Dec 31, 2024$3.0M10 Dec 31, 2023−100.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Intangible assets, net (excluding goodwill)$79.1K5 Dec 31, 2025$148.4K5 Dec 31, 2024−46.7%
Finite-lived intangibles, gross$1.4M5 Dec 31, 2025$1.4M5 Dec 31, 20240%
Accumulated amortization$1.3M5 Dec 31, 2025$1.2M5 Dec 31, 2024+5.6%
Finite-lived intangibles, net$79.1K5 Dec 31, 2025$148.4K5 Dec 31, 2024−46.7%

Inventory

ItemLatestA year beforeChange
Inventory, total$3.8M5 Dec 31, 2025$3.7M5 Dec 31, 2024+1.8%

Properties, in its own words

Our headquarters are located at 425 Eagle Rock Avenue, Roseland, New Jersey 07068, and our telephone number is (973) 535-2717. In August 2019, we entered into a seven-year lease for our facility in Roseland, New Jersey (the “Roseland Facility”). Monthly lease payments are $9,275, commencing April 1, 2021. We are also responsible for electricity charges of $2.00 per square foot (approximately $11,130 annually), payable in equal monthly installments of $928, and our proportionate share of certain operating costs and property taxes in excess of base-year amounts.

We do not own, and do not currently intend to acquire, any real property.

Item 2 of the 10-K filed Mar 31, 2026.4

Leadership

Who has led MILESTONE SCIENTIFIC INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Joe W. Martin2007–2009
  2. Leonard Osser2010–2021
  3. Daniel S. Goldberger2017

President

  1. Thomas Ronca2007
  2. Steven F. Robins2015
  3. Daniel S. Goldberger2017
  4. Brent W. Johnston2019–2020
  5. Jan Adriaan Haverhals2021–2023
  6. Peter J. Milligan2023

Chief financial officer

  1. David Cohn2007
  2. Arthur L. Goldberg2007–2008
  3. Joseph D'Agostino2008–2021
  4. Scott L. Kahn2021

Chief operating officer

  1. Thomas Ronca2007
  2. Joseph D'Agostino2011–2021
2010201520202025
Board members and other officers (17)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Chief Executive OfficerEric Hines named Apr 23, 202639
  • Vice President of FinanceKeisha Harcum named Apr 23, 202639
  • DirectorDawood I. Sayed named Apr 23, 202639
  • DirectorDidier I. Demesmin named Apr 23, 202639
  • DirectorShanth I. Thiyagalingam named Apr 23, 202639

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • Milestone Innovations Inc. Delaware3
  • Wand Dental , Inc. Delaware3

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Former names

  • MILESTONE SCIENTIFIC INC/NJNov 7, 1997 to Dec 17, 20092
  • U S OPPORTUNITY SEARCH INCNov 14, 1996 to Mar 14, 19972

Timeline

  1. Jul 31, 20268-K Executive or director change; Shareholder vote40
  2. Jul 29, 20268-K Other events41
  3. Jun 25, 20268-K Entered a material agreement; Executive or director change; Regulation FD disclosure42
  4. May 6, 20268-K Executive or director change43
  5. May 6, 20268-K Change of auditor44
  6. Apr 21, 20268-K Entered a material agreement; Unregistered sale of shares45
  7. Apr 2, 20268-K Entered a material agreement46
  8. Mar 11, 20268-K Bylaws or fiscal year changed47
  9. Feb 4, 20268-K Financial statements and exhibits48
  10. Jan 20, 20268-K Entered a material agreement49
  11. Dec 23, 20258-K Shareholder vote50
  12. Nov 13, 20258-K Executive or director change51
  13. Jul 12, 2017New chief executive Daniel S. Goldberger becomes CEO13
  14. Feb 3, 2010New chief executive Leonard Osser becomes CEO14
  15. Jun 11, 2007New chief executive Joe W. Martin becomes CEO15

Calendar

Coming up

  1. Nov 12, 2026Reports results for the quarter ending Sep/202652

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

178 filings to the SEC since October 2021: 6 annual reports, 15 quarterly reports, 36 major events, 90 insider forms, 1 large holders, 1 private raises, 29 other. The latest 20:

  1. Sep 28, 2026EFFECT EDGAR
  2. Sep 18, 2026S-3/A EDGAR
  3. Sep 8, 2026S-8 EDGAR
  4. Sep 8, 2026S-3 EDGAR
  5. Aug 13, 202610-Q EDGAR
  6. Jul 31, 20268-K EDGAR
  7. Jul 29, 20268-K EDGAR
  8. Jun 25, 20268-K EDGAR
  9. Jun 22, 2026DEF 14A EDGAR
  10. Jun 10, 2026PRER14A EDGAR
  11. Jun 9, 2026EFFECT EDGAR
  12. Jun 9, 2026424B1 EDGAR
  13. Jun 8, 2026CORRESP EDGAR
  14. Jun 8, 2026UPLOAD EDGAR
  15. Jun 5, 2026PRE 14A EDGAR
  16. Jun 2, 2026S-3 EDGAR
  17. May 13, 202610-Q EDGAR
  18. May 6, 20268-K EDGAR
  19. May 6, 20268-K EDGAR
  20. May 5, 202610-K/A EDGAR

The 178 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

91 open-market trades by officers, directors and large owners since October 2021: 9 buys and 82 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Oct 24, 2025BP4 S.r.l.10% ownerSale100,000$0.44$44.0KForm 4
Oct 23, 2025BP4 S.r.l.10% ownerSale80,000$0.43$34.4KForm 4
Oct 22, 2025BP4 S.r.l.10% ownerSale14,427$0.45$6.5KForm 4
Oct 21, 2025BP4 S.r.l.10% ownerSale40,000$0.44$17.6KForm 4
Oct 20, 2025BP4 S.r.l.10% ownerSale24,034$0.45$10.8KForm 4
Oct 14, 2025BP4 S.r.l.10% ownerSale30,000$0.54$16.2KForm 4
Oct 13, 2025BP4 S.r.l.10% ownerSale10,000$0.55$5.5KForm 4
Oct 10, 2025BP4 S.r.l.10% ownerSale10,158$0.55$5.6KForm 4
Oct 8, 2025BP4 S.r.l.10% ownerSale30,000$0.47$14.1KForm 4
Oct 7, 2025BP4 S.r.l.10% ownerSale10,000$0.45$4.5KForm 4
Oct 3, 2025BP4 S.r.l.10% ownerSale19,210$0.45$8.6KForm 4
Sep 11, 2025BP4 S.r.l.10% ownerSale10,000$0.59$5.9KForm 4
Jul 17, 2025BP4 S.r.l.10% ownerSale10,000$0.64$6.4KForm 4
Jul 8, 2025BP4 S.r.l.10% ownerSale11,489$0.69$7.9KForm 4
Jul 7, 2025BP4 S.r.l.10% ownerSale30,558$0.68$20.8KForm 4
Jul 3, 2025BP4 S.r.l.10% ownerSale50,853$0.67$34.1KForm 4
Jun 30, 2025BP4 S.r.l.10% ownerSale649$0.65$422Form 4
Jun 27, 2025BP4 S.r.l.10% ownerSale10,000$0.73$7.3KForm 4
Jun 25, 2025BP4 S.r.l.10% ownerSale1,300$0.77$1.0KForm 4
Jun 24, 2025BP4 S.r.l.10% ownerSale10,000$0.81$8.1KForm 4

All 91 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025Eric HinesCEO58$77.0K$795.0K54
2025Jason PapesSenior VP of Global Sales and Marketing$77.6K$723.8K54
2025Keisha M. HarcumVice President of Finance$220.0K$270.0K54
2024Jan Adriaan (Arjan) HaverhalsCEO$350.0K$881.4K54
2024Keisha M. HarcumVice President of Finance$203.8K$228.8K54

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Apr 20, 2026Raised $2.1 million in a private offering of equity Form D: $4.8 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 29. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Vanguard Capital Management LLC2,073,166$665.5K0.0%+86,518
Geode Capital Management, LLC643,611$206.7K0.0%+26,966
Vanguard Fiduciary Trust Co464,449$149.1K0.0%+142,866
State Street Corp264,885$85.0K0.0%+125,000
NFSG Corp141,000$45.3K0.0%+100,000
Northern Trust Corp133,067$42.7K0.0%+20,452
LPL Financial LLC124,945$40.1K0.0%No change
Mariner, LLC121,750$39.1K0.0%No change
Carnegie Investment Counsel100,175$32.2K0.0%No change
Bridgeway Capital Management, LLC99,500$31.9K0.0%No change
World Investment Advisors104,000$30.0K0.0%No change
BlackRock, Inc.65,453$21.0K0.0%No change
Renaissance Technologies LLC56,297$18.1K0.0%−26,200
Commonwealth Equity Services, LLC44,782$14.4K0.0%No change
Sequoia Financial Advisors, LLC43,422$13.9K0.0%No change
Kestra Advisory Services, LLC41,100$13.2K0.0%No change
XTX Topco Ltd34,843$11.2K0.0%−10,516
Cetera Investment Advisers17,150$5.5K0.0%No change
HighTower Advisors, LLC15,666$5.0K0.0%No change
Radnor Capital Management, LLC15,000$4.8K0.0%No change
Vanguard Global Advisers, LLC14,867$4.8K0.0%No change
Daniel Investment Group, Inc.13,076$4.2K0.0%New
Oppenheimer & Co Inc10,000$3.2K0.0%No change
Dock Street Asset Management Inc10,000$3.2K0.0%No change
UBS Group AG8,590$2.8K0.0%−53,910

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MILESTONE SCIENTIFIC INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMILESTONE SCIENTIFIC INC.1
  • CIK0000855683
  • Employer ID (EIN)13-35456234
  • Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company4
  • Incorporated inDelaware4
  • Fiscal year endsDecember 311
  • Industry code (SIC)3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies1
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
  • Business address220 South Orange Avenue, Livingston, NJ 070391
  • Phone(973) 535-27171
  • Shares outstanding88,739,185 as of Aug 11, 202612
  • Public float$39.7M as of Jun 30, 20254
  • AuditorCBIZ CPAs P.C, Morristown, New Jersey PCAOB ID 199; no auditor attestation of internal control over financial reporting4
  • On EDGAR sinceAug 14, 19961
  • Filings810 in all: 4 (272), 8-K (117), 10-Q (56), 10QSB (35), DEF 14A (31), 3 (20), 10-K (18), CORRESP (18)1
    All 56 form types

    SC 13G/A (18), UPLOAD (18), S-3/A (14), S-3 (13), SC 13D/A (12), 4/A (10), 424B5 (10), NT 10-K (10), NT 10-Q (10), SC 13G (10), 10QSB/A (9), 424B3 (9), PRE 14A (8), 10KSB (7), SC 13D (7), 144 (6), S-2/A (6), S-8 (6), 10KSB40 (5), EFFECT (5), 10KSB40/A (4), 5 (4), 8-A12B (4), 424B2 (3), POS AM (3), 10-K/A (2), 10KSB/A (2), 25 (2), 8-K/A (2), ARS (2), D (2), DEFA14A (2), PRER14A (2), S-2 (2), 10-Q/A (1), 25-NSE (1), 3/A (1), 424B1 (1), 424B4 (1), AW (1), CERTAMX (1), CERTNYS (1), DEFS14A (1), PRE 14C (1), PRES14A (1), REGDEX (1), REGDEX/A (1), SCHEDULE 13D/A (1)

  • Latest filingsAnnual report (10-K) Mar 31, 2026
    Quarterly report (10-Q) Aug 13, 2026
    Proxy statement (DEF 14A) Jun 22, 2026
    Latest 8-K (8-K) Jul 31, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.001 per shareMLSSNYSE American

From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).4

Risk factors and legal proceedings

The risks MILESTONE SCIENTIFIC INC. names in Item 1A of its 10-K filed Mar 31, 2026: 42 risks under these headings, as written.4

  • Risks Related to Our Financial Position and Need for Additional Capital
  • We anticipate that we will need additional funding for our operations and may be unable to raise capital when needed, which may force us to delay, curtail, or eliminate parts of the Company’s operations.
  • Sales of a substantial number of shares of our common stock, or the perception that such sales may occur, may adversely impact the price of our common stock.
  • Raising additional capital by issuing securities or through licensing or lending arrangements may cause dilution to our existing stockholders, restrict our operations, or require us to relinquish proprietary rights.
  • Financial institution instability could adversely affect our operations and financial condition.
  • Our financial statements have been prepared on a going concern basis, but there can be no assurance that we will be able to continue as a going concern without raising additional capital.
  • Risks Related to Sales and Distribution of Our Products
  • Our sales and marketing efforts in the United States rely upon its E-Commerce platform.
  • We are exposed to the risks inherent in international sales.
  • If physicians neither accept nor use our CompuFlo Epidural System, our ability to generate revenue from sales will be materially impaired.
  • If our technology does not perform as expected, or if we fail to successfully develop, commercialize, or sell new or enhanced products or penetrate new markets, our business, financial condition, and operating results could be adversely affected.
  • Developments by competitors may render our products or technologies obsolete or non-competitive.
The other 32 risks
  • Our ability to commercialize our products will depend in part on the extent to which reimbursement will be available from governmental agencies, health administration authorities, private health maintenance organizations, health insurers, and other healthcare payers.
  • Healthcare reform laws and regulations significantly affect the U.S. healthcare services industry.
  • We could lose our market advantage earlier than expected.
  • Risks Related to Employee Matters
  • We may not be able to attract and retain qualified employees.
  • Risk Related to Our Dependence on Third Parties
  • Relying exclusively on third parties to manufacture our products, changes in our informal manufacturing arrangements made by the manufacturer of our products, disruptions at the manufacturing facility of our manufacturers, and failure to maintain existing supply relationships expose us to risks that may harm our business.
  • Our business is exposed to risks associated with the economic, environmental, and political conditions in China because the sole manufacturer of our handpieces is in China.
  • Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products.
  • The use of third parties to manufacture our products may increase the risk that we will not have enough of our products or such quantities at acceptable levels of cost and quality, which could impair our commercialization efforts.
  • Risks Related to Regulatory Compliance and Other Legal Matters
  • We are subject to substantial domestic and international government regulation, including regulatory quality standards applicable to our manufacturing and quality processes. Failure by us to comply with these standards could have an adverse effect on our business, financial condition, or results of operations.
  • We may be subject, directly or indirectly, to U.S. federal and state healthcare fraud and abuse and false claims laws and regulations. Prosecutions under such laws have increased in recent years and we may become subject to such litigation. If we are unable to comply or have not fully complied with such laws, we could face substantial penalties.
  • Certain modifications to the Company’s products may require new 510(k) clearances or other marketing authorizations and may require the Company to recall or cease marketing its products.
  • Changes to United States federal and state regulatory agencies may cause disruptions and delays in the approval processes and regulations relating to our products.
  • The Company may be subject to enforcement actions if it engages in improper marketing or promotion of its products.
  • Changes in laws and regulations over which we have no control can significantly affect our business and results of operations.
  • Changes to trade policy, including tariff and import/export regulations, may have a material adverse effect on our results of operations, cash flows, and financial condition.
  • Regulatory uncertainty may increase following recent federal developments.
  • Federal actions related to tariffs and research funding may disrupt our business.
  • International conflict has affected commerce worldwide and may have a material adverse effect on our results of operations, cash flows, and financial condition.
  • Geopolitical instability, labor unrest, and economic disruptions in certain foreign jurisdictions may indirectly affect our operations.
  • Risks Related Company’s Securities
  • The Company is effectively controlled by a limited number of stockholders.
  • We expect we will need additional financing to execute our business plan and fund operations, and additional financing may not be available on reasonable terms or at all.
  • If we fail to regain compliance with the strict listing requirements of NYSE American, we may be subject to delisting. As a result, our stock price may decline, and our common stock may be de-listed. If our stock were no longer listed on NYSE American, the liquidity of our securities likely would be impaired.
  • We have relied heavily on sales of our common stock to fund our operations, and our ability to obtain additional capital through stock sales or other securities offerings may be more costly or dilutive to our stockholders than in the past, or may not be available to us at all. Our ability to raise additional capital may be limited by a low trading volume, stock price and market capitalization, as well as by laws, regulations and market conditions.
  • Failure to implement effective internal controls required by the Sarbanes-Oxley Act of 2002 could result in material misstatements in our financial statements, cause investors to lose confidence in the Company’s reported financial information and have a negative effect on the trading price of our common stock.
  • The market price of our common stock may be volatile and may fluctuate significantly, and stockholders could lose all or part of their investment in the Company.
  • We have never paid and do not intend to pay cash dividends in the foreseeable future. As a result, capital appreciation, if any, will be your sole source of gain.
  • Provisions in our certificate of incorporation, our by-laws and Delaware law might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock.
  • Your percentage of ownership in the Company may be diluted in the future.
  • Risks Related to Our Intellectual Property
  • If we are unable to adequately protect our patents, trade secrets and other proprietary rights, if our patents are challenged or if our provisional patent applications do not get approved, our competitiveness and business prospects may be materially damaged.
  • Third parties could obtain patents that may require us to negotiate licenses to commercialize our technologies, and we cannot assure you that the required licenses would be available on reasonable terms or at all.
  • General Business Risks
  • Cybersecurity incidents, data breaches, or other system disruptions could compromise our products, data, and operations and materially adversely affect our business, financial condition, and results of operations.
  • Insurance coverage may be inadequate or unavailable to cover any product liability losses we incur.

Legal proceedings

We are not involved in any legal proceedings.

The opening of Item 3, Legal Proceedings.4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54